<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43"><gtr:id>31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Porton Down</gtr:line1><gtr:line4>Salisbury</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/421B4793-37B1-4BD6-AAD9-8B6C240ED8C9"><gtr:id>421B4793-37B1-4BD6-AAD9-8B6C240ED8C9</gtr:id><gtr:name>Duke University</gtr:name><gtr:address><gtr:line1>Edmund T Pratt</gtr:line1><gtr:postCode>27708-0300</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/537E4701-06F9-44F6-9A09-F43ECD2D4F96"><gtr:id>537E4701-06F9-44F6-9A09-F43ECD2D4F96</gtr:id><gtr:name>Mucosis BV</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/52423922-8331-4312-A996-E4734BB4D688"><gtr:id>52423922-8331-4312-A996-E4734BB4D688</gtr:id><gtr:name>Utrecht University</gtr:name><gtr:address><gtr:line1>PO Box 80125</gtr:line1><gtr:line2>3508 TC Utrecht</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DEF5B792-E941-4197-8F2B-A74193BA0CC4"><gtr:id>DEF5B792-E941-4197-8F2B-A74193BA0CC4</gtr:id><gtr:name>Amsterdam Medical Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7035AE5D-F006-4762-9959-D965363291F6"><gtr:id>7035AE5D-F006-4762-9959-D965363291F6</gtr:id><gtr:name>Merck</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4286CD3F-C639-4B71-9A48-DBE0A468F4F9"><gtr:id>4286CD3F-C639-4B71-9A48-DBE0A468F4F9</gtr:id><gtr:name>La Jolla Inst for Allergy and Immunology</gtr:name><gtr:address><gtr:line1>La Jolla Inst for Allergy and Immunology</gtr:line1><gtr:line2>Department of Developmental Immunology 3</gtr:line2><gtr:line3>10355 Science Center Drive</gtr:line3><gtr:postCode>CA 92121</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B2EE12FB-8E49-4F6A-8073-DF35FAF50581"><gtr:id>B2EE12FB-8E49-4F6A-8073-DF35FAF50581</gtr:id><gtr:name>Emory University</gtr:name><gtr:address><gtr:line1>201 Dowman Drive</gtr:line1><gtr:line4>Atlanta</gtr:line4><gtr:line5>Ga 30322</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>National Heart and Lung Institute</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43"><gtr:id>31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Porton Down</gtr:line1><gtr:line4>Salisbury</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/421B4793-37B1-4BD6-AAD9-8B6C240ED8C9"><gtr:id>421B4793-37B1-4BD6-AAD9-8B6C240ED8C9</gtr:id><gtr:name>Duke University</gtr:name><gtr:address><gtr:line1>Edmund T Pratt</gtr:line1><gtr:postCode>27708-0300</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/537E4701-06F9-44F6-9A09-F43ECD2D4F96"><gtr:id>537E4701-06F9-44F6-9A09-F43ECD2D4F96</gtr:id><gtr:name>Mucosis BV</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/52423922-8331-4312-A996-E4734BB4D688"><gtr:id>52423922-8331-4312-A996-E4734BB4D688</gtr:id><gtr:name>Utrecht University</gtr:name><gtr:address><gtr:line1>PO Box 80125</gtr:line1><gtr:line2>3508 TC Utrecht</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DEF5B792-E941-4197-8F2B-A74193BA0CC4"><gtr:id>DEF5B792-E941-4197-8F2B-A74193BA0CC4</gtr:id><gtr:name>Amsterdam Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7035AE5D-F006-4762-9959-D965363291F6"><gtr:id>7035AE5D-F006-4762-9959-D965363291F6</gtr:id><gtr:name>Merck</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4286CD3F-C639-4B71-9A48-DBE0A468F4F9"><gtr:id>4286CD3F-C639-4B71-9A48-DBE0A468F4F9</gtr:id><gtr:name>La Jolla Inst for Allergy and Immunology</gtr:name><gtr:address><gtr:line1>La Jolla Inst for Allergy and Immunology</gtr:line1><gtr:line2>Department of Developmental Immunology 3</gtr:line2><gtr:line3>10355 Science Center Drive</gtr:line3><gtr:postCode>CA 92121</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B2EE12FB-8E49-4F6A-8073-DF35FAF50581"><gtr:id>B2EE12FB-8E49-4F6A-8073-DF35FAF50581</gtr:id><gtr:name>Emory University</gtr:name><gtr:address><gtr:line1>201 Dowman Drive</gtr:line1><gtr:line4>Atlanta</gtr:line4><gtr:line5>Ga 30322</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F0CF3F48-B22B-4A63-B51A-388F334BDF0D"><gtr:id>F0CF3F48-B22B-4A63-B51A-388F334BDF0D</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>Chiu</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0902266"><gtr:id>532E50F0-6AF7-473B-A3B5-0F1515F09B0D</gtr:id><gtr:title>Cell mediated immunity against RSV and influenza in a human experimental challenge model</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0902266</gtr:grantReference><gtr:abstractText>Influenza and respiratory syncytial virus (RSV) are among the most common causes of lung infection. They affect around 664 million people each year worldwide, causing an estimated 500,000 and 160,000 deaths respectively. Current influenza vaccines need to change every year to overcome rapid viral mutation, and there is still no RSV vaccine. Further research is therefore urgently needed. T cells are important in controlling viral infections, but there is not enough known about their role in humans with influenza and RSV. Furthermore, there is evidence that the T cell response to RSV is not fully protective, leading to multiple infections with the same strain of RSV in some people. 

This work will be carried out at the Centre for Respiratory Infection, Imperial College London within Professor Peter Openshaw?s department. Healthy volunteers will be infected with either RSV or a weakened strain of influenza in order to examine the response of the T cells in their blood and lung secretions. By observing the changes in T cells following each infection, and comparing the responses to influenza and RSV, we aim to identify the essential components of an effective T cell response so that they can be used to create better vaccines.</gtr:abstractText><gtr:technicalSummary>Background
Influenza and respiratory syncytial virus (RSV) are among the most common causes of viral respiratory infection, causing widespread morbidity and mortality particularly at the extremes of age and exacerbating conditions such as asthma. Vaccine development remains an urgent priority. While cell mediated immunity (CMI) is important in viral clearance and may enhance vaccine efficacy, its relative contribution in humans has not been fully determined. We aim to elucidate its role by comparing the human T cell responses to influenza and RSV. These differ in that re-infection with antigenically identical strains of influenza does not occur, while within 2 months of RSV challenge even subjects with high antibody levels may be re-infected with the same strain. The reasons for this are unclear but may involve immune modulation by viral products or impaired antigen presentation by RSV-infected dendritic cells leading to impaired T cell numbers function.

Hypotheses &amp;amp; aims
1. To test the hypothesis that RSV and influenza lead to quantitative and functional differences in T-cell responses.
2. To identify the mechanisms underlying poor antigen-specific CMI to RSV by comparing the transcriptional changes in T-cells following experimental challenge with RSV and live attenuated influenza vaccine (LAIV).

Study design
Healthy adult volunteers will be challenged with RSV Memphis 37 or LAIV. Samples will be collected periodically from blood, broncho-alveolar lavage (BAL) and nose. After 6 months, a second dose of virus will be administered and further samples obtained to examine the recall response.

The number of virus-specific T-cells will be analysed by ELISPOT and by MHC/peptide multimer staining. Differential effector functions will be studied including surface protein expression, cytokine production and proliferative capacity by CFSE staining. Flow cytometry will be used to characterize activation markers, co-stimulatory molecules, cytokines, and cytotoxic molecules. Nasal and bronchial fluid will be analysed for cytokine levels using multiplex bead arrays and Luminex. Using microarrays, we will identify transcriptional changes that occur during T-cell activation and following re-stimulation with RSV and LAIV. These data will recapitulate the predicted functional defects in RSV-infected T cells and will allow us to make inferences regarding underlying mechanisms via differential expression of signalling intermediates in TCR signal transduction.

CMI is important against both influenza and RSV infection, but protection against RSV is incomplete. By identifying correlates of immunity absent from the CMI response to RSV we aim to elucidate the basis for previous vaccine failures as well as novel approaches to vaccination.</gtr:technicalSummary><gtr:fund><gtr:end>2014-10-05</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-10-06</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1067515</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Public Health England</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Respiratory Virus Unit (RVU)</gtr:department><gtr:description>Full genome sequencing of RSV isolates</gtr:description><gtr:id>600BA07E-D76E-41A6-9EA8-FDF1FF289740</gtr:id><gtr:impact>None so far</gtr:impact><gtr:outcomeId>5457addd6ecff9.19726240-1</gtr:outcomeId><gtr:partnerContribution>Full genome sequencing of RSV isolates</gtr:partnerContribution><gtr:piContribution>Provision of respiratory samples from hospitalised patients and experimentally challenged adults for RSV full genome sequencing</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>La Jolla Institute for Allergy &amp; Immunology (LIAI)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Division of Translational Immunology</gtr:department><gtr:description>Role of T follicular helper cells for cross-reactive antibody responses</gtr:description><gtr:id>3F609212-6C78-4FCE-9B90-8E2BCD24497C</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>LvhfELwVoK1-1</gtr:outcomeId><gtr:partnerContribution>This collaboration has provided epitope predictions and techniques for the generation and use of peptide libraries.</gtr:partnerContribution><gtr:piContribution>Study design, sample collection and performing assays.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Emory University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Emory Vaccine Centre</gtr:department><gtr:description>Adaptive immune responses to viral vaccines and challenge</gtr:description><gtr:id>2040B428-CC7D-47EF-8954-38DF9AFA0D6C</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>bWQsL75JGar-1</gtr:outcomeId><gtr:partnerContribution>This collaboration has provided patient samples, sharing of techniques and strategic input.</gtr:partnerContribution><gtr:piContribution>Study design, subject recruitment, sample collection, and carrying out assays.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Human Genetics Unit</gtr:department><gtr:description>Role of cathelicidin in experimental human RSV infection</gtr:description><gtr:id>761FD96F-3B6A-4544-9C33-698F77A05734</gtr:id><gtr:impact>None so far.</gtr:impact><gtr:outcomeId>5457aa782d2d88.35529605-1</gtr:outcomeId><gtr:partnerContribution>Cathelicidin levels have been measured in serum and bronchoalveolar lavage fluid. These will be correlated with clinical outcome and bronchial epithelial cell gene expression data.</gtr:partnerContribution><gtr:piContribution>Using the experimental human RSV model, we have collected serum and respiratory samples prior to and during infection with RSV, quantified viral shedding and determined the dynamics of disease.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Utrecht University</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:department>Department of Infectious Diseases and Immunology</gtr:department><gtr:description>Humoral responses to recombinant RSV proteins in experimental human infection</gtr:description><gtr:id>21D2FBA0-13E4-4F57-BC5C-DFDD10A512FD</gtr:id><gtr:impact>Paper submitted detailing the role of mucosal IgA in protection against RSV</gtr:impact><gtr:outcomeId>5457ad385a2c98.70224430-2</gtr:outcomeId><gtr:partnerContribution>Provision of recombinant F proteins</gtr:partnerContribution><gtr:piContribution>Analysis of antibody and B cell responses to RSV F protein in adults challenged with RSV</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Amsterdam Medical Center</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:department>Department of Medical Microbiology and Infection Control</gtr:department><gtr:description>PREPARE WP3</gtr:description><gtr:id>29912CAF-9932-4144-9252-3BA1D3D15228</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>568a73b88325b6.14421345-1</gtr:outcomeId><gtr:partnerContribution>Transcriptomic analysis of blood and respiratory epithelial cells. Analysis of volatile organic compounds in exhaled breath.</gtr:partnerContribution><gtr:piContribution>Conduct of experimental human influenza infection study, collection of clinical samples, assessment of infection rate and clinical severity. Analysis of antibody and T cell responses.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mucosis BV</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Humoral responses to recombinant RSV proteins in experimental human infection</gtr:description><gtr:id>DF02B6C2-C70D-4ED3-85E6-90C2FC6F5972</gtr:id><gtr:impact>Paper submitted detailing the role of mucosal IgA in protection against RSV</gtr:impact><gtr:outcomeId>5457ad385a2c98.70224430-1</gtr:outcomeId><gtr:partnerContribution>Provision of recombinant F proteins</gtr:partnerContribution><gtr:piContribution>Analysis of antibody and B cell responses to RSV F protein in adults challenged with RSV</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mucosis BV</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Phase I and 2a clinical trial of Mucosis SynGEM</gtr:description><gtr:id>8A18D6A0-D2A8-4DE0-9419-27B55A4F219A</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>568a7271ab9ad0.21812015-1</gtr:outcomeId><gtr:partnerContribution>Provision of SynGEM vaccine. Contracting of CRO and sponsorship of clinical trials. Analysis of serum samples by competition ELISA assays.</gtr:partnerContribution><gtr:piContribution>Conducting phase 1 and phase 2a RSV challenge study clinical trials of a novel RSV vaccine SynGEM. Collection of clinical samples. Assessment of infection rate and severity. Analysis of antibody, B cell and T cell responses.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Duke University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Insitute of Genome Sciences and Policy</gtr:department><gtr:description>Transcriptional and proteomic changes in human experimental RSV infection</gtr:description><gtr:id>F44123C1-DBE0-4E4B-A036-D0B820D5AA9C</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>qsMk8vS8vvh-1</gtr:outcomeId><gtr:partnerContribution>Our partners have provided GMP-certified RSV virus and will process and analyse blood and nasal samples for transcriptomic and proteomic analysis.</gtr:partnerContribution><gtr:piContribution>We have conducted experimental human infection of volunteers with RSV, collected blood and respiratory specimens for further transcriptomic and proteomic analysis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC National Institute for Medical Research (NIMR)</gtr:department><gtr:description>Whole blood transcriptomic signatures in experimental human infection with RSV</gtr:description><gtr:id>2E5133FF-8F53-48FF-95B1-C71AD788C57E</gtr:id><gtr:impact>None so far</gtr:impact><gtr:outcomeId>5457afa5c47301.08513986-1</gtr:outcomeId><gtr:partnerContribution>Processing of RNA for microarray</gtr:partnerContribution><gtr:piContribution>Blood samples provided for microarray analysis</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Merck</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>RNAseq of nasal curettage in experimental human RSV infection</gtr:description><gtr:id>2C5413DD-3600-498E-8D1C-B4F407B37816</gtr:id><gtr:impact>None so far</gtr:impact><gtr:outcomeId>568a654e4f9d26.82385029-1</gtr:outcomeId><gtr:partnerContribution>RNA extraction and RNA sequencing of nasal curettage samples for transcriptomic analysis. Collaboration on analysis.</gtr:partnerContribution><gtr:piContribution>Collection of sequential nasal curettage samples from volunteers experimentally infected with RSV and assessment of infection status and clinical severity. Collaboration on analysis.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Imperial Festival</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>FFDD072B-35BC-45EE-BC5E-89AE65CAA194</gtr:id><gtr:impact>Attended stall publicising our clinical research work with large models showing the nose and respiratory tract mucosa as well as games and multimedia displays focusing on influenza and the MOSAIC project. The Imperial Festival lasts an entire weekend and 344 e-surveys were collated. The majority of respondees felt that the event had developed their interest in science &amp;quot;a lot&amp;quot; and 88% would recommend the Festival to others.</gtr:impact><gtr:outcomeId>56af6b4a936110.05012723</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013,2014,2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2772791</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Translation Award</gtr:department><gtr:description>Translation Award</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>DF3FFC21-1C37-4BB1-9DFB-28729D37CE5F</gtr:id><gtr:outcomeId>56af7479c448f8.86519620</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>800000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>DARPA BAA Prometheus</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>Defense Advanced Research Projects Agency (DARPA)</gtr:fundingOrg><gtr:id>4BB8C0A3-10B2-4297-B9FD-C5AED3ED6A69</gtr:id><gtr:outcomeId>58b59d821c70e0.58347207</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Pilot research projects in human immunology</gtr:description><gtr:end>2012-06-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:id>D4D273D9-AB52-4405-BDDD-B755609B22AE</gtr:id><gtr:outcomeId>XfHxAcY78ZU0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1151285</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC GSK EMINENT</gtr:description><gtr:end>2019-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>23369813-1C62-4884-9C1A-7525ED490BD6</gtr:id><gtr:outcomeId>58b59e2eb1d3f1.87094318</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>337838</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Innovative Medicines Initiative (IMI)</gtr:department><gtr:description>EU IMI Biovacsafe</gtr:description><gtr:end>2018-03-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>F6377FB1-5F72-4D2E-AA15-AE78EB135024</gtr:id><gtr:outcomeId>58b59d253dd172.34258788</gtr:outcomeId><gtr:sector>Multiple</gtr:sector><gtr:start>2012-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>WHO Working Group on RSV Vaccine Standardization and Clinical Evaluation</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>BE890FEB-73DC-45D1-8B4F-94B006D0FAA4</gtr:id><gtr:outcomeId>58b59ebc98a7c5.31554832</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Only a few T cell targets in respiratory syncytial virus have been published. We defined a set of previously unrecognised CD4+ and CD8+ T cell targets and have made tetramers to label these cells for further analysis and isolation.</gtr:description><gtr:id>9D436A05-B0B2-4752-A662-0718BE8D7532</gtr:id><gtr:impact>Knowledge of these targets may enhance RSV vaccine development.</gtr:impact><gtr:outcomeId>56af6c0430bc75.83181593</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>RSV tetramers</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>636A9F7F-9500-46DF-9101-C39EEC43EABC</gtr:id><gtr:title>Antiviral B cell and T cell immunity in the lungs.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b0ab83ce5a962ead03102dd5b014052"><gtr:id>5b0ab83ce5a962ead03102dd5b014052</gtr:id><gtr:otherNames>Chiu C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>568a639abc9e77.79632774</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5560F8C-9940-4350-BDF9-7D9F01D40BE9</gtr:id><gtr:title>Metabolic Phenotypes of Response to Vaccination in Humans.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8a46f3752fd4026773cf1b531707cbf"><gtr:id>b8a46f3752fd4026773cf1b531707cbf</gtr:id><gtr:otherNames>Li S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn><gtr:outcomeId>5a578bada63e97.97465450</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB5353AD-1C7A-44A5-BD25-5945C95F9BEC</gtr:id><gtr:title>Current concepts and progress in RSV vaccine development.</gtr:title><gtr:parentPublicationTitle>Expert review of vaccines</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/abb8774495984c453ea56b2de167adf1"><gtr:id>abb8774495984c453ea56b2de167adf1</gtr:id><gtr:otherNames>Guvenel AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1476-0584</gtr:issn><gtr:outcomeId>pm_540e16fe16fda5e65</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC83DBC8-0C55-43DA-B634-A92A35076B72</gtr:id><gtr:title>Seasonal influenza vaccines and hurdles to mutual protection.</gtr:title><gtr:parentPublicationTitle>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b0ab83ce5a962ead03102dd5b014052"><gtr:id>5b0ab83ce5a962ead03102dd5b014052</gtr:id><gtr:otherNames>Chiu C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1198-743X</gtr:issn><gtr:outcomeId>58b59faef200d6.41742271</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F57540A1-00FB-4B21-BB03-D1026358C72A</gtr:id><gtr:title>B cell responses to influenza infection and vaccination.</gtr:title><gtr:parentPublicationTitle>Current topics in microbiology and immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b0ab83ce5a962ead03102dd5b014052"><gtr:id>5b0ab83ce5a962ead03102dd5b014052</gtr:id><gtr:otherNames>Chiu C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0070-217X</gtr:issn><gtr:outcomeId>5457a8a2a1a8e0.18422562</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F7DF38EF-25C1-4EEE-A28B-002C64C8CD73</gtr:id><gtr:title>Protective and dysregulated T cell immunity in RSV infection.</gtr:title><gtr:parentPublicationTitle>Current opinion in virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e1eb793e41c94bae8f9d96b02241b8ad"><gtr:id>e1eb793e41c94bae8f9d96b02241b8ad</gtr:id><gtr:otherNames>Openshaw PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1879-6257</gtr:issn><gtr:outcomeId>pm_13405_25_23806514</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8378081C-E295-4AC6-820A-57794CA88627</gtr:id><gtr:title>Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a136073afc0b43d7b5fc2e1d0be61ec"><gtr:id>2a136073afc0b43d7b5fc2e1d0be61ec</gtr:id><gtr:otherNames>Ellebedy AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>5457a8a27af174.75966763</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F313ECA6-4A00-4267-9F03-56E4CB9AA081</gtr:id><gtr:title>Controlled human infection with RSV: The opportunities of experimental challenge.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/05cc63115d1ca013df093252c62448ab"><gtr:id>05cc63115d1ca013df093252c62448ab</gtr:id><gtr:otherNames>Habibi MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>588b58d9268d00.76537363</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B21591EE-9C7E-4B89-871E-694EBEBAAC49</gtr:id><gtr:title>Broadly reactive human CD8 T cells that recognize an epitope conserved between VZV, HSV and EBV.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b0ab83ce5a962ead03102dd5b014052"><gtr:id>5b0ab83ce5a962ead03102dd5b014052</gtr:id><gtr:otherNames>Chiu C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>pm_540e16fe16fe70f42</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D71D03B8-B9FA-41F8-AFEA-2358617F6240</gtr:id><gtr:title>RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d9b2b3ed8434da2f4fed33fa5157f83e"><gtr:id>d9b2b3ed8434da2f4fed33fa5157f83e</gtr:id><gtr:otherNames>Jozwik A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>568a639a8eade9.10318666</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D218C352-0B88-4BDE-B495-24160D74B5DC</gtr:id><gtr:title>Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c77e0fe3343f631d65c2e751f3d425f"><gtr:id>8c77e0fe3343f631d65c2e751f3d425f</gtr:id><gtr:otherNames>Li GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_13405_25_22615367</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF44D4B7-DB47-400C-8B7E-F8BD9AC0E4E3</gtr:id><gtr:title>Cross-reactive humoral responses to influenza and their implications for a universal vaccine.</gtr:title><gtr:parentPublicationTitle>Annals of the New York Academy of Sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b0ab83ce5a962ead03102dd5b014052"><gtr:id>5b0ab83ce5a962ead03102dd5b014052</gtr:id><gtr:otherNames>Chiu C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0077-8923</gtr:issn><gtr:outcomeId>pm_13405_25_23405860</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6AA209A-702F-4B0E-8F3B-84187D94946D</gtr:id><gtr:title>Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/05cc63115d1ca013df093252c62448ab"><gtr:id>05cc63115d1ca013df093252c62448ab</gtr:id><gtr:otherNames>Habibi MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>5675e04557a29</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CCF9B84-0670-4730-9C07-FA8E3678FD1F</gtr:id><gtr:title>Tuberculosis Infectiousness and Host Susceptibility.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d2028546a41ccb619985cb7a4939e91"><gtr:id>3d2028546a41ccb619985cb7a4939e91</gtr:id><gtr:otherNames>Turner RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>5a6f056eb4e768.85204801</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>996A1F53-5809-4492-A050-3DF55C7209F4</gtr:id><gtr:title>Cathelicidins Have Direct Antiviral Activity against Respiratory Syncytial Virus In Vitro and Protective Function In Vivo in Mice and Humans.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de0af521e3b8927456e4486709e4349d"><gtr:id>de0af521e3b8927456e4486709e4349d</gtr:id><gtr:otherNames>Currie SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>56c71fbba845c4.73142853</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98C5E24C-6CB1-4067-9BAC-127B80195418</gtr:id><gtr:title>Protective and Harmful Immunity to RSV Infection.</gtr:title><gtr:parentPublicationTitle>Annual review of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fba90e472cb39c17c5b6bac5bcdf10dc"><gtr:id>fba90e472cb39c17c5b6bac5bcdf10dc</gtr:id><gtr:otherNames>Openshaw PJM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0732-0582</gtr:issn><gtr:outcomeId>58b59fe3a5df68.64020626</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A90A798B-EC5E-46F1-8F08-C36D02759372</gtr:id><gtr:title>Novel immunological insights in accelerating RSV vaccine development.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b0ab83ce5a962ead03102dd5b014052"><gtr:id>5b0ab83ce5a962ead03102dd5b014052</gtr:id><gtr:otherNames>Chiu C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>588b58dc03d346.02739318</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0902266</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>